Epigenetic editing
Epigenetic editing has an early result in people with hepatitis B. Tune reports that TUNE-401 reduced viral biomarkers by more at higher doses, with some effects followed for 17 months. The next test is lasting clinical benefit in larger studies. Until then the biomarker changes are a signal, and how the treatment works in every patient is still unproven.
Research snapshot · updated Nov 12, 2026
Reversibility is both feature and bug - durability is now the open clinical question
Epigenetic edits can fade over time, unlike permanent base/prime edits. Feature: a safer off-switch and lower off-target risk. Bug: it may demand re-dosing. The first clinical answer arrived at EASL 2026, where TUNE-401 showed HBV-biomarker repression sustained 17+ months and counting after a single dose. Phase 2 must confirm that durability at scale: hold for years and epigenetic editing fits chronic indications; fade within months and it stays niche.
State of the art (2026)
Epigenetic editing crossed from theory to clinic in 2026. At EASL on 30 May, Tune Therapeutics reported positive Phase 1b/2a data for TUNE-401, an LNP-RNA epigenetic silencer that methylates HBV cccDNA and integrated DNA: HBV-biomarker repression in every patient dosed at levels 2-4, with Phase 2 slated for late 2026. Tune raised $175M Series B in January 2025 at a roughly $900M valuation. nChroma Bio (the December 2024 Chroma-Nvelop merger) is advancing CRMA-1001 toward HBV/HBD trials. The field is led by private CRISPRi/a and dCas9-KRAB platforms; Omega Therapeutics collapsed into bankruptcy in 2025. Durability beyond first dosing, not mechanism, is now the open question.
Explore the deeper analysis in CanaryIQ
Explore what is covered below. These previews show the structure; log in to read the full analysis.
Signal stack
Evidence stacked leading → lagging
9 signals
Signal stack
Evidence stacked leading → lagging
Technology-native KPIs
Metrics that predict trajectory, tracked over time
4 tracked
Technology-native KPIs
Metrics that predict trajectory, tracked over time
Landscape map
Who builds what, and who depends on whom
142 players · 6 layers
Landscape map
Who builds what, and who depends on whom
Catalyst calendar
Dated events that will move the position
6 ahead
Catalyst calendar
Dated events that will move the position
Technology roadmap
Milestones on the path to maturity
7 milestones
Technology roadmap
Milestones on the path to maturity
Watchlists
Companies, people and papers, each with a condition for removing it
20 · 19
Watchlists
Companies, people and papers, each with a condition for removing it
Decision frameworks
What our view means for your job
Locked
Decision frameworks
What our view means for your job
Thesis changelog
When our view changed, and why
8 updates
Thesis changelog
When our view changed, and why
Change our mind
5 disconfirming conditions
You've read the verdict. The file is much deeper.
The full signal stack, technology-native KPIs tracked over time, the landscape of who depends on whom, the dated catalyst calendar, decision frameworks for every desk, live watchlists and a record of every time our view on Epigenetic editing has changed. All of it is in CanaryIQ.